Immune genes and transplant outcomes across different ancestries

Immunogenetics of Outcomes Disparities After Allogeneic HCT

NIH-funded research Fred Hutchinson Cancer Center · NIH-11318970

This project looks at immune-related genes in donors and recipients to help people getting donor stem-cell transplants, especially across racial and ethnic groups.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionFred Hutchinson Cancer Center NIH-funded
Lab location1 site (Seattle, United States)
Project IDNIH-11318970 on NIH RePORTER

What this research studies

From a patient's point of view, researchers will compare DNA from transplant patients and their donors to find immune-gene differences linked to relapse and survival. They will focus on the NKG2 ligand/receptor pathway and look for ancestry-specific genetic changes that affect gene expression and outcomes. The team will analyze data across African, Hispanic, Asian, and European American groups to see which genetic features explain survival gaps. Results aim to inform better donor selection and risk prediction to reduce racial disparities after transplant.

Who could benefit from this research

Good fit: Ideal candidates are people planning to have or who have had an allogeneic hematopoietic cell (stem-cell) transplant for blood cancers and their potential donors, particularly from African, Hispanic, Asian, or European ancestry groups.

Not a fit: People who are not undergoing donor stem-cell transplants or whose donor-recipient pairs and genetic data are not included would be unlikely to get direct benefit from this project.

Why it matters

Potential benefit: If successful, this work could lead to more personalized donor selection and risk predictions that reduce relapse and improve survival after allogeneic stem-cell transplant, especially for underrepresented racial groups.

How similar studies have performed: Past work shows HLA and some immune-gene differences affect transplant outcomes and the investigators have preliminary data on NKG2 variants, but using ancestry-specific NKG2 profiles to guide donor choice is a relatively new approach.

Where this research is happening

Seattle, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.